Is Novo Nordisk’s Stock Decline a Buying Opportunity?

The Danish pharmaceutical giant Novo Nordisk is navigating a challenging period that would have seemed improbable just two years ago. Since the start of the year, the former market darling has shed nearly half its market capitalization, with the downward trend continuing through this Friday. A significant price target reduction from Goldman Sachs, the failure of a crucial Alzheimer’s study, and growing concerns that the explosive growth narrative for weight-loss injections like Wegovy and Ozempic is fading have all contributed to the sell-off. Investors are now questioning whether the company faces a permanent re-rating or if the current slump presents a historic entry point.

Leadership Shake-Up and Pricing Pressures Intensify Challenges

Compounding the company’s difficulties is a strategic overhaul at the highest level. During an extraordinary general meeting, Lars Rebien Sørensen was elected as the new Chairman with 93% approval. This move is widely interpreted as a signal that the Novo Nordisk Foundation is pushing for a change in strategic direction.

Simultaneously, the firm is grappling with intense pricing pressure in the United States. Following negotiations with the Trump administration and Medicare, the monthly out-of-pocket cost for Wegovy has been capped at $199—a mere fraction of the previous price, which often exceeded $1,000. This development is dramatically squeezing the company’s profit margins.

Goldman Sachs Trims Target but Maintains Buy Stance

Adding to the headwinds on Friday, Goldman Sachs provided fresh reasons for caution. The influential US investment bank slashed its price target for Novo Nordisk from $60 to $54. Despite this substantial reduction, the analysts reaffirmed their “Buy” recommendation. The underlying message suggests that the severe market reaction may be overblown. After all, the stock has plummeted approximately 60% from its peak in December 2024, a crash that has stunned even seasoned market participants.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The reasons for this widespread skepticism are clear. The company’s third-quarter results, while showing a strong earnings per share of $1.02 (surpassing expectations of $0.77), failed to meet revenue forecasts. Sales came in at $11.79 billion, missing the projected $11.98 billion, indicating that the hyper-growth of previous years has indeed subsided.

Setback as Alzheimer’s Ambitions Fizzle

A more significant blow came from the failure of the EVOKE clinical trials. Novo Nordisk had been testing its blockbuster drug, semaglutide—the active ingredient in Ozempic and Rybelsus—on 3,800 Alzheimer’s patients over a two-year period. The outcome was definitive: the treatment showed no significant improvement in memory or daily function compared to a placebo. With the studies now being terminated, a potential multi-billion dollar expansion of the GLP-1 portfolio into this therapeutic area has been erased.

The analyst community remains divided on the path forward. While Barclays maintains a neutral stance with a price target of 375 kroner, Handelsbanken has adopted a more pessimistic view, downgrading the stock to “Sell” and assigning a fair value of just 285 kroner.

A Glimmer of Hope in a Higher Dosage

Despite the cascade of negative news, one potential catalyst remains. Novo Nordisk has submitted an application to the FDA for approval of a higher 7.2 mg dosage of Wegovy and is seeking an accelerated review process. If successful, this new formulation could help differentiate its product more distinctly from competing treatments offered by rivals like Eli Lilly. Whether this will be sufficient to restore investor confidence, however, is still an open question.